Carbohydrate CDMO Services

Carbohydrate CDMO Services — Elise Biopharma

At Elise Biopharma, we believe that sugars are not accessories to biology — they are its grammar and syntax. Carbohydrates are the language of life, encoding signals that control immune activation, pathogen binding, receptor recognition, protein folding, and therapeutic stability. They determine half-lives, tune antibody effector function, and mediate the delicate balance between efficacy and safety.

As the pharmaceutical industry pivots toward precision medicine, glycans are no longer peripheral excipients; they are critical active components of vaccines, antibody-drug conjugates (ADCs), cell therapies, gene delivery systems, and diagnostics.

Elise Biopharma, Biologics start faster with us

That’s why Elise Biopharma has built a world-class CDMO platform dedicated to carbohydrates. Our capabilities span early discovery support through full-scale GMP manufacturing, combining deep expertise in glycoscience with cutting-edge biomanufacturing infrastructure. From custom glycan synthesis to glycoconjugates, glycoengineering, and carbohydrate-active enzymes, we deliver a comprehensive, niche-rich capability stack designed to accelerate and de-risk your program.

Why Carbohydrates Matter

Structural diversity: Carbohydrates exhibit the most complex stereochemistry in biology. Unlike DNA and proteins, glycans form branched, stereochemically dense architectures, with linkage position, anomeric configuration, and branching all impacting biological activity.

Therapeutic relevance: Glycans underpin conjugate vaccines, ADC linkers, viral vectors, monoclonal antibody function, tumor antigens, and drug delivery systems. Glycoforms dictate ADCC/CDC activity, pharmacokinetics, and even immunogenicity.

Analytical challenge: Carbohydrates require specialized analytical approaches — separation technologies, derivatization methods, high-resolution MS, and NMR to distinguish linkage, branching, and modifications. Glycoprofiling is not optional; it is mission-critical for regulatory acceptance.

At Elise Biopharma, we don’t shy away from glycan complexity. We translate carbohydrate heterogeneity into therapeutic clarity, giving our partners precision analytics, reproducible processes, and scalable manufacturing solutions.

Our Carbohydrate CDMO Service Portfolio

1. Custom Carbohydrate Synthesis

  • Oligosaccharides & polysaccharides: linear, branched, sulfated, phosphorylated, sialylated, fucosylated, GAGs (heparan sulfate, chondroitin, keratan, dermatan).
  • Rare sugars & analogs: fluorinated sugars, azido-functionalized, keto-modified, deoxy-sugars.
  • Activated intermediates: glycosyl donors, nucleotide sugars, and sugar phosphates for enzymatic cascades.
  • Scalable synthesis: mg for discovery, gram-to-kg for preclinical, multi-kg GMP campaigns.
  • Route scouting & stereocontrol: enzymatic and chemical approaches to ensure purity, chirality, and yield.

2. Glycoconjugates & Carbohydrate–Protein Conjugation

  • Glycopeptides, glycolipids, glycoproteins produced with controlled glycan attachment.
  • Conjugate vaccines: polysaccharide–protein vaccines (CRM197, tetanus toxoid, KLH).
  • ADC linkers with carbohydrate handles: engineered for improved hydrophilicity, DAR control, and tuned PK.
  • Orthogonal chemistries: reductive amination, click chemistry (azide-alkyne), oxime ligation, thioether bridging, enzymatic conjugation.
  • Immunogenicity tuning: tailor glycoconjugates to optimize antigen presentation and T-cell activation.

3. Carbohydrate-Active Enzymes (CAZymes)

  • Enzyme expression & scale-up: glycosyltransferases, glycosidases, kinases, epimerases, sulfotransferases.
  • Cascade biocatalysis: multienzyme pathways for complex glycan synthesis.
  • Protein engineering: directed evolution and site-directed mutagenesis for enhanced specificity, thermostability, and yield.
  • GMP enzyme manufacturing: APIs (e.g., glucocerebrosidase, hyaluronidase) and industrial bioprocess enzymes.
  • Cell-free enzyme kits: plug-and-play biocatalytic modules for rapid glycan prototyping.

4. Glycosylation Engineering for Biologics

  • Cell line engineering: CHO, HEK, yeast, insect, and microbial platforms optimized for tailored glycan profiles.
  • In vitro glyco-remodeling: enzymatic sialylation, fucosylation, galactosylation, bisecting GlcNAc modifications.
  • Biosimilars & biobetters: create homogenous glycoforms to ensure comparability and extend IP life.
  • Effector function tuning: controlled glycan remodeling to modulate FcγR binding, ADCC/CDC activity.
  • Custom glycoengineering kits: standardized modules for antibody remodeling.

5. Analytical Glycobiology Services

  • Comprehensive glycoprofiling: HILIC-UPLC, LC-MS/MS, MALDI-TOF, CE-LIF.
  • Monosaccharide composition: ion chromatography after derivatization.
  • Linkage analysis: methylation + GC-MS, NMR-based branching maps.
  • Glycoform spectrum analysis: quantify heterogeneity for biosimilars and comparability.
  • Structural elucidation: map novel glycans and carbohydrate conjugates at atomic resolution.
  • Regulatory readiness: full data packages for IND/IMPD submissions.

6. Carbohydrate-Based Excipients & Formulation

  • Stabilizers: trehalose, sucrose, mannitol for lyophilized biologics.
  • Modified polysaccharides: dextran derivatives, hyaluronic acid, chitosan, pullulan, hydroxyethyl starch.
  • Controlled-release matrices: oral, injectable, and implantable sugar-based hydrogels.
  • Custom excipients: rare sugar derivatives to enhance solubility, permeability, and targeting.
  • Nanocarriers: carbohydrate-coated nanoparticles for drug delivery and gene vectors.

7. GMP Manufacturing & Scale-Up

  • Multi-kg GMP carbohydrate synthesis under FDA/EMA/ICH Q7.
  • Dedicated vaccine suites: polysaccharide–protein conjugates with aseptic filling.
  • Integrated DSP: chromatography, filtration, precipitation, and lyophilization tailored to glycans.
  • Quality systems: validated cleaning, contamination control, industrial hygiene for powder handling.
  • CMC & regulatory support: IND/IMPD/DMF filings, comparability studies, audit preparation.

Niche and Emerging Applications of Carbohydrates

  • Conjugate vaccines: bacterial capsular polysaccharides, synthetic oligosaccharide antigens.
  • Oncology: tumor-associated carbohydrate antigens, glycan-modified ADC linkers.
  • Gene therapy & viral vectors: glycan ligands for tropism and targeting.
  • Cell therapy & regenerative medicine: hyaluronan scaffolds, glycosaminoglycans in ECM engineering.
  • Nanoparticles & delivery: carbohydrate shells for stability, stealth, and cell-specific uptake.
  • Diagnostics: glycan microarrays, biosensor ligands, lectin-binding assays.
  • Nutraceuticals & microbiome therapies: prebiotic oligosaccharides, synbiotics.

Why Elise Biopharma?

Depth + breadth. From simple monosaccharides to fully engineered glycoproteins, Elise Biopharma spans the entire glycan value chain with true Carbohydrate CDMO scope: custom rare-sugar synthesis, multi-step oligosaccharide assembly, enzymatic cascades, glycoconjugate vaccines, glycoengineered biologics, and carbohydrate-based excipients. We don’t just “touch” glycans—we design, make, analyze, and scale them with route control, stereochemical fidelity, and lot-to-lot reproducibility.

Integrated partner. Discovery chemistry, CAZyme supply, glycoanalytics, glycoengineering, formulation, and GMP manufacturing live under one roof and one quality system. That end-to-end Carbohydrate CDMO model shortens handoffs, compresses timelines, and keeps your CMC narrative coherent—from feasibility to IND/IMPD to commercialization—without re-explaining your molecule at every door.

Purpose-built infrastructure. Dedicated carbohydrate synthesis suites with contained solids handling; CAZyme bioreactors and cell-free enzyme modules for cascade biocatalysis; HILIC-UPLC, LC-MS/MS, MALDI-TOF, CE-LIF, and NMR for full structural elucidation; conjugation lines for polysaccharide–protein vaccines; and lyophilization/formulation suites tuned to sugar glass dynamics. Our facility design reflects the realities of a modern Carbohydrate CDMO: closed transfers, health-based cleaning limits, and validated analytics for sub-percent glycoform changes.

Unmatched expertise. Our team blends carbohydrate chemistry, enzymology, protein biochemistry, and analytical glycobiology. We engineer stereocontrol at the anomeric center, tune donor/acceptor reactivity, select protecting-group strategies that survive scale, and exploit enzyme promiscuity when it helps—but engineer away from it when it hurts. That cross-disciplinary rigor is what you want in a Carbohydrate CDMO when synthesis, biocatalysis, and conjugation converge.

Process and analytical excellence. We run quality-by-design from day one: CQAs link to glycan attributes (linkage, branching, sialylation/fucosylation, sulfation), CPPs map to chemistry and enzyme steps, and DoE defines robust operating ranges. Release testing includes monosaccharide composition, linkage analysis, glycoform spectrum, impurity profiles, residual solvents, endotoxin/bioburden (where applicable), and stability in real formulations. Methods are qualified/validated with recovery studies that respect the peculiarities of sugars.

Digital, data, and tech transfer. Digital batch records, structured glycan metadata, and comparability templates de-risk site moves and lifecycle changes. Our tech-transfer playbook for Carbohydrate CDMO programs includes route and impurity mapping, enzyme sourcing/qualification, analytical method portability (system suitability + bracketing), and scale-down validation models so process understanding travels with the asset.

Supply-chain assurance. We maintain audited suppliers for nucleotide sugars, protected sugar building blocks, carriers (CRM197, TT, KLH), and specialized reagents—backed by dual-sourcing where it counts. For CAZymes, we can manufacture in-house or qualify external GMP sources to avoid single-point failures. Cold-chain and moisture control are engineered around carbohydrate hygroscopicity.

Flexible engagement. Start small (feasibility, FTE) or run full programs (route to GMP, conjugate vaccine scale-up, glycoengineered mAb comparability). We scope milestones with clear deliverables, analytics, and decision gates, then expand as data warrants. This is a Carbohydrate CDMO built to meet you where you are—without forcing a one-size-fits-all model.

Regulatory credibility. We’ve authored and defended glycan-heavy CMC sections for FDA, EMA, PMDA: glycoprofiles, comparability protocols, conjugation controls (degree of substitution, free saccharide), residuals (carrier, linker, reagents), and stability indicating methods. Expect reviewer-ready rationales, health-based limits, and clear control strategies that survive inspection.

Operational performance. We commit to meaningful SLAs—analytical turnaround, batch disposition timelines, and deviation close-out—with KPI reporting. You’ll see trend charts for critical attributes (e.g., galactosylation levels, sulfation patterns, DAR for conjugates) and ppm-level defect tracking so quality isn’t a slogan—it’s telemetry.

Let’s Build With Sugars

At Elise Biopharma, we see carbohydrates not as obstacles but as design space for smarter therapies. By mastering their chemistry, biology, and analytics, we unlock products with superior precision, stability, and clinical impact. If your pipeline depends on glycans—whether a glycoconjugate vaccine, a glycoengineered antibody, a rare sugar API, or a carbohydrate-coated nanoparticle—you deserve a Carbohydrate CDMO that can carry it from idea to GMP with scientific authority.

Choose Elise Biopharma as your Carbohydrate CDMO for discovery-to-commercial programs, seamless tech transfer, and regulator-ready CMC. Partner with the Carbohydrate CDMO that treats sugars as the language of biology—and speaks it fluently. For end-to-end Carbohydrate CDMO services, we’re ready when you are.

Top 10 FAQ — Carbohydrate CDMO Services
1. What does a Carbohydrate CDMO actually do?

A Carbohydrate CDMO specializes in the development and GMP manufacturing of carbohydrate-based molecules: oligosaccharides, polysaccharides, glycoconjugates, carbohydrate-active enzymes, glycoengineered biologics, and carbohydrate-derived excipients. Unlike general biologics CDMOs, a Carbohydrate CDMO integrates synthetic carbohydrate chemistry, enzymatic biocatalysis, advanced glycoanalytics, and conjugation technologies under one roof to support discovery-to-commercial programs.

2. Why are carbohydrates so challenging to manufacture at scale?

Carbohydrates are structurally complex: they have multiple stereocenters, branching points, and anomeric configurations that require exquisite control. They are also hygroscopic, prone to degradation, and analytically challenging, often requiring LC-MS, NMR, and CE-LIF in combination to resolve isomers. Scale-up demands stereocontrolled synthetic routes, robust enzymatic cascades, and validated closed handling to achieve reproducibility and GMP compliance. This is why a dedicated Carbohydrate CDMO is essential.

3. What types of projects can a Carbohydrate CDMO support?
  • Conjugate vaccines: bacterial polysaccharide–protein conjugates.
  • Oncology payloads: glycan-modified ADC linkers, tumor-associated carbohydrate antigens.
  • Glycoengineered biologics: antibodies with tailored glycoforms for ADCC/CDC tuning.
  • Rare sugar APIs: fluorinated or modified monosaccharides for niche therapies.
  • Carbohydrate excipients: stabilizers, controlled-release matrices, nanoparticle coatings.
  • Diagnostics: carbohydrate microarrays, glycan ligands for biosensors.

4. How do you ensure glycan structural integrity and reproducibility?

Through quality-by-design (QbD): critical quality attributes (CQAs) are mapped to glycan features such as linkage, branching, sialylation, and sulfation. Critical process parameters (CPPs) are defined for chemistry and enzymatic steps. Analytical rigor is non-negotiable: HILIC-UPLC, MALDI-TOF, LC-MS/MS, NMR, and CE-LIF provide orthogonal confirmation. Trend data ensures reproducibility across batches, which is a hallmark of Carbohydrate CDMO expertise.

5. What specialized infrastructure does a Carbohydrate CDMO require?
  • Dedicated carbohydrate synthesis suites with controlled humidity and closed transfers.
  • CAZyme bioreactors for enzymatic cascade synthesis.
  • Conjugation lines for polysaccharide–protein vaccines and glycopeptides.
  • High-resolution glycoanalytics (LC-MS/MS, MALDI, NMR, HILIC, CE-LIF).
  • GMP lyophilization and formulation suites tuned to sugar-based excipients.

6. Can a Carbohydrate CDMO also handle glycoengineering of biologics?

Yes. Carbohydrate CDMOs like Elise Biopharma support cell-line engineering (CHO, HEK, yeast, microbial) to control glycosylation patterns, and offer in vitro enzymatic remodeling (sialylation, fucosylation, galactosylation). This enables biosimilars, biobetters, and monoclonal antibodies with optimized glycoform distributions for effector function, half-life, or reduced immunogenicity.

7. How does a Carbohydrate CDMO manage regulatory compliance?

By embedding carbohydrate-specific analytics and controls into CMC packages. This includes glycoprofiles, comparability studies, conjugation controls (degree of substitution, free saccharide), impurity tracking, and validated cleaning protocols. A Carbohydrate CDMO ensures filings are audit-ready for FDA, EMA, and PMDA, with health-based cleaning limits and method validation designed around glycan complexity.

8. What scale can a Carbohydrate CDMO manufacture?
  • Milligram-to-gram scale for early discovery and analytical standards.
  • Gram-to-multi-kg scale for preclinical and clinical supply.
  • Multi-kg GMP campaigns for vaccines, glycoconjugates, and carbohydrate APIs.
    The scale depends on molecule class and demand, but the Carbohydrate CDMO model ensures smooth transition through feasibility, pilot, and commercial runs.
9. How does a Carbohydrate CDMO de-risk tech transfer?

Containment and analytics are treated as critical process parameters. A structured tech-transfer playbook includes:

  • Early toxicology and exposure banding.
  • Task-based exposure assessments.
  • Surrogate testing for isolators and closed transfers.
  • Analytical method portability (system suitability, sensitivity alignment).
  • Lifecycle documentation of glycan routes and impurities.
    This ensures seamless scaling between R&D, pilot, and GMP without costly surprises.
10. Why choose Elise Biopharma as your Carbohydrate CDMO partner?

Because we combine unmatched glycoscience expertise with purpose-built infrastructure. From rare sugar synthesis and enzyme engineering to glycoform tuning, conjugate vaccines, advanced glycoanalytics, and GMP manufacturing, Elise Biopharma offers the most complete Carbohydrate CDMO services portfolio in the industry. We are not just a service provider; we are a partner that transforms carbohydrate complexity into therapeutic opportunity.

Want to discuss a Carbohydrate research project?

Email our team today at info@elisebiopharma.com